hrp0092fc14.4 | GH and IGF4 | ESPE2019
Vlachopapadopoulou Elpis
, Aghajanova Elena
, Chertok Elena
, Korpal-Szczyrska Maria
, Giorgadze Elene
, Kovalenko Tatiana
, Maniatis Aristedes
, Thornton Paul
, Hofman Paul
, Song Wenjie
, Shu Aimee
, Karpf David
, Beckert Michael
, Leff Jonathan
Background: TransCon hGH is a sustained-release prodrug in development as a long-acting GH for children with growth hormone deficiency (GHD). TransCon hGH consists of a parent drug, growth hormone (hGH; somatropin), that is transiently bound to a carrier via a TransCon linker. The carrier extends hGH circulation time in the body and fully active hGH is released over one week at physiologic pH and temperature. Unlike other molecules in development, TransCon hGH...